ABBV vs MRK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and MRK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and MRK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

Merck and Co., Inc. (NYSE: MRK) is a global research-intensive biopharmaceutical company headquartered in Rahway, New Jersey. It discovers, develops, manufactures, and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious disease, cardiovascular, and diabetes, alongside a substantial Animal Health segment that sells vaccines and medicines for livestock and companion animals. The company operates under the MSD name outside the United States and Canada. Revenue flows primarily from pharmaceutical product sales, with oncology representing more than 60 percent of pharmaceutical revenue. Keytruda, a PD-1 inhibitor approved in more than 40 cancer indications, is the world's best-selling drug and the dominant revenue driver. Other meaningful contributors include the Gardasil HPV vaccine franchise, pulmonary arterial hypertension therapy Winrevair, pneumococcal vaccine Capvaxive, antiviral Lagevrio, and the Animal Health portfolio led by the Bravecto parasite treatment and Allflex livestock intelligence products.

Full MRK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
• MRK drivers: Keytruda's remaining runway is substantial; A tripling of the Phase III pipeline provides post-cliff optionality.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For MRK, the central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; MRK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and MRK guides.

ABBV. The large gap between the trailing GAAP P/E (about 80x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.5x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The forward multiple has risen from about 15.7x in June as the shares climbed, so more of the expected Skyrizi and Rinvoq growth is now in the price. Q3 2026 results on October 30 are the next test, with consensus EPS near $3.79.

MRK. Merck's trailing P/E near 117x is an artifact of 2026 acquisition charges that pushed GAAP results into losses in the first half; the forward P/E of about 15.8x on 2027 consensus EPS of about $9.32 is the more useful yardstick, and it sits below the mid-30s trailing multiple the stock carried in mid-2026 on clean earnings. The market has rewarded the pipeline and new launches with a 38% gain this year, so the October 29 Q3 report (consensus EPS about $2.09) and updated guidance matter for whether that rerating holds. The 25 analysts Yahoo Finance tracks have a mean target near $159.

Headline figures (approximate, October 2026): ABBV shows revenue (ttm) ~$64.4 billion (Q2 2026 ~$17.0B, up ~10% YoY), adjusted eps Q2 2026 $3.65 vs $3.61 estimate; FY2026 guidance $13.87-14.07; FY2027 consensus ~$16.21, gaap net income (ttm) ~$6.3 billion (GAAP EPS ~$3.54, depressed by acquired IPR and D), p/e ~80x trailing GAAP; ~17.5x forward adjusted; MRK shows revenue (ttm) ~$66.6 billion (Q2 2026 +5.1% YoY), net income (ttm, gaap) ~$3.2 billion, after 2026 acquisition charges (FY2025: ~$18.3 billion), gross margin (ttm) ~75.9%, p/e (trailing / forward) ~117x / ~15.8x.

ABBV and MRK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and MRK exposure against your real portfolio. It is not an investment adviser.